Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-09
2011-08-09
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235800, C514S236500, C514S398000, C514S404000, C548S324500, C548S323500, C548S370100, C544S139000, C544S370000, C544S124000, C546S153000, C546S274400
Reexamination Certificate
active
07994204
ABSTRACT:
The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1) and which are useful for pharmaceutical purposes.A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:[wherein Ar represents a monocyclic heterocyclic ring containing one or two nitrogen atoms, A represents an oxygen atom or the like, Y1, Y2and Y3each represent a carbon atom or a nitrogen atom, R1represents a hydrogen atom, a C1-C6alkyl group or the like, R2represents a C1-C6alkyl group, a C3-C8cycloalkyl group or the like, R3represents a C1-C18alkyl group or the like, R4represents a hydrogen atom or a C1-C6alkyl group, and R5represents a C1-C10alkyl group or the like].
REFERENCES:
patent: 5516783 (1996-05-01), Whittaker et al.
patent: 5910506 (1999-06-01), Sugimoto et al.
patent: 6147097 (2000-11-01), Sugimoto et al.
patent: 2003/0229125 (2003-12-01), Haaf et al.
patent: 2005/0124654 (2005-06-01), Groneberg et al.
patent: 2007/0232682 (2007-10-01), Beard et al.
patent: 2009/0131438 (2009-05-01), Ono et al.
patent: 2010/0041655 (2010-02-01), Ono et al.
patent: 0786455 (1997-07-01), None
patent: 786455 (1997-07-01), None
patent: 1 798 226 (2007-06-01), None
patent: 5-194412 (1993-08-01), None
patent: 2002-212070 (2002-07-01), None
patent: 2002-332278 (2002-11-01), None
patent: 2003-137894 (2003-05-01), None
patent: 2003137894 (2003-05-01), None
patent: 2003/530388 (2003-10-01), None
patent: 2004/532276 (2004-10-01), None
patent: 96/10019 (1996-04-01), None
patent: 01/77089 (2001-10-01), None
patent: 02/18395 (2002-03-01), None
patent: 0218395 (2002-03-01), None
patent: 02/100853 (2002-12-01), None
patent: 03/000679 (2003-01-01), None
patent: 03/073986 (2003-09-01), None
patent: 03/074008 (2003-09-01), None
patent: 03073986 (2003-09-01), None
patent: 03074008 (2003-09-01), None
patent: 03/097028 (2003-11-01), None
patent: 03097028 (2003-11-01), None
patent: 03/105771 (2003-12-01), None
patent: 2004/024673 (2004-03-01), None
patent: 2004/074257 (2004-09-01), None
patent: 2004/089367 (2004-10-01), None
patent: 2004/103279 (2004-12-01), None
patent: 2005/123677 (2005-12-01), None
patent: 2006/0136948 (2006-02-01), None
patent: 2006013948 (2006-02-01), None
patent: 2006/097489 (2006-09-01), None
patent: 2007/083089 (2007-07-01), None
patent: 2007/091570 (2007-08-01), None
patent: 2007/112322 (2007-10-01), None
patent: 2007/122401 (2007-11-01), None
patent: 2007/129019 (2007-11-01), None
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
J. G. Cannon Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.
Y. Igarashi, J. Biochem. 1997, 122, 1080-1087.
Baumruker et al., Expert Opin. Investig. Drugs 2007, 16(3) 283-289.
Pyne et al. Nature Reviews Cancer 2010, 10, 489-503.
International Search Report dated Sep. 22, 2008, as issued in International Application No. PCT/JP2008/063851.
H. Gehlen, et al., “2-Amino-1, 3,4-oxidiazoles. VII. Formation of 2-amino-5-aminoalkyl-1, 3,4-oxidiazoles and their conversion into 1,2,4-triazoles and triazolones”, Justus Liebigs Annalen der Chemi. vol. 651, pp. 128-132, Sep. 23, 1962 with Full English language translation.
James R. Van Brocklyn et al., Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells, Cancer Letters, Elsevier, 2003, pp. 53-60, vol. 199.
Zdzislaw Brzozowski, 2-Mercapto-N-(Azolyl) Benzenesulphonamides I. Synthesis of N-(1,1-Dioxo-7,4,2-Benzodithianzin-3-YL)Guanidines and Their Transformations Into 2-Mercapto-N-(5-Amino-1,2,4-Triazol-3-YL) Benzenesulphonamide Dervatives with Potential Anti-HIV or Anticancer Activity, Department of Drug Technology, Faculty of Pharmacy, School of Medicine, Acta Poloniae Pharmaceutica-Drug Research, Polish Pharmaceutical Society, 1995, pp. 91-101, vol. 52, No. 2.
Guofeng Jia, et al., “Syntheses of Some New 4-Amino-5-(N-methyl-arylsulfonamido)methyl-1,2,4-triazole-3-thiones and Their Derivatives”, Heteroatom Chemistry, vol. 7, No. 4, pp. 263-267, 1996.
Gehlen, H., et al., 2-Amino-1,3,4-oxadiazoles. IX. Oxidation of Aldehyde Semicarbazones to 2-amino-1, 3,4-oxadiazoles and Their Conversion Into 1-acylsemicarbazides, Justus Liebigs Annalen Der Chemi, vol. 651, pp. 133-136, 1962.
Von Heinz Gehlen, et al; Zur Kenntnis der 2-Amino-1,3,4-oxdiazole, X 3-Xlkoxy-1,2,4-Triazole Durch Alkoholyse von 2-Amino-1,3,4-0xdiazolen; Liebigs Ann. Chem. 651, 137 (1962); pp. 137-141 (with an English translation).
M. Germana Sanna et al., “Sphingosine 1-Phosphate (SIP) Receptor Subtypes SIP1and SIP3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate”, The Journal of Biological Chemistry, vol. 279, No. 14, Issue of Apr. 2, pp. 13839-13848, 2004.
Jeremy J. Clemens et al., “Synthesis ofPara-Alkyl Aryl Amide Analogues of Sphingosine-I-phosphate: Discovery of Potent SIP Receptor Agonists”, Bioorganic & Medicinal Chemistry Letters, 13 (2003) 3401-3404.
H. Gehlen, et al., “2-Amino-1, 3,4-oxidiazoles. VIII. Formation of 2-amino-5-aminoalkyl-1,3,4-oxidiazoles and their conversion into 1,2,4-triazoles and triazolones”, Chemical Abstracts, Database Accession No. 57:16892, Justus Liebigs Annalen der Chemie, vol. 651, pp. 128-132, 1962.
Supplemental European Search Report dated Oct. 13, 2009, issued in European Application No. 07708069.5.
Extended European Search Report issued Nov. 23, 2010 from the European Patent Office in a counterpart European Application No. 07713881.6.
Hla, Timothy, “Physiological and Pathological Actions of Sphingosine 1-Phosphate”, 15 Sem. Cell & Dev. Bio. 513 (2004).
Katakai Hironori
Koami Takeshi
Nishikawa Rie
Ono Naoya
Ota Tomomi
Nolan Jason M
Sughrue & Mion, PLLC
Taisho Pharmaceutical Co., Ltd
LandOfFree
Binding inhibitor of sphingosine-1-phosphate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding inhibitor of sphingosine-1-phosphate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding inhibitor of sphingosine-1-phosphate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700873